Last updated on July 2019

A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)


Brief description of study

The purpose of this study is to evaluate the hemostatic efficacy of andexanet alfa in patients receiving a factor Xa inhibitor who are experiencing an acute major bleed. The safety of andexanet will also be studied.

Clinical Study Identifier: NCT02329327

Find a site near you

Start Over

Portola Investigational Site

Long Beach, CA United States
  Connect »

Portola Investigational Site

Los Angeles, CA United States
  Connect »

Portola Investigational Site

Fort Lauderdale, FL United States
  Connect »

Portola Investigational Site

Jacksonville, FL United States
  Connect »

Portola Investigational Site

Sarasota, FL United States
  Connect »

Portola Investigational Site

Annapolis, MD United States
  Connect »

Portola Investigational Site

Royal Oak, MI United States
  Connect »

Portola Investigational Site

Saint Louis, MO United States
  Connect »

Portola Investigational Site

Rochester, NY United States
  Connect »

Portola Investigational Site

Asheville, NC United States
  Connect »

Portola Investigational Site

Chapel Hill, NC United States
  Connect »

Portola Investigational Site

Cincinnati, OH United States
  Connect »

Portola Investigational Site

Cleveland, OH United States
  Connect »

Portola Investigational Site

Pittsburgh, PA United States
  Connect »

Portola Investigational Site

Fort Worth, TX United States
  Connect »

Portola Investigational Site

Huntington, WV United States
  Connect »

Portola Investigational Site

Stoke on Trent, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.